-
The Synthetic Routes of Desmopressin Acetate
Time of Update: 2023-04-30
Desmopressin acetate, also known as DDAVP, is a synthetic hormone that is used to treat various conditions related to water regulation in the body.
Desmopressin acetate, also known as DDAVP, is a synthetic hormone that is used to treat various conditions related to water regulation in the body.
-
The Production Process of Desmopressin Acetate
Time of Update: 2023-04-30
Conclusion The production process of desmopressin acetate involves several chemical reactions and purification steps, starting from the preparation of raw materials and ending with the formulation and packaging of the final drug product.
-
The Instruction of Desmopressin Acetate
Time of Update: 2023-04-30
It is commonly used in the chemical industry for various purposes, including as a reagent in chemical synthesis, as a separation agent in the purification of chemicals, and as a intermediate in the production of various pharmaceuticals.
-
The Safety of Desmopressin Acetate
Time of Update: 2023-04-30
In conclusion, desmopressin acetate is a safe and effective treatment option for conditions related to water balance in the body.
In conclusion, desmopressin acetate is a safe and effective treatment option for conditions related to water balance in the body.
-
The Applications of Desmopressin Acetate
Time of Update: 2023-04-30
In the chemical industry, desmopressin acetate is used in a variety of applications, including as a chemical intermediate, a pharmaceutical excipient, and a veterinary medicine.
In the chemical industry, desmopressin acetate is used in a variety of applications, including as a chemical intermediate, a pharmaceutical excipient, and a veterinary medicine.
-
The Upstream and Downstream products of Desmopressin Acetate
Time of Update: 2023-04-30
These materials are sourced from various suppliers and manufacturers, and the production process involves a series of chemical reactions and purification steps to ensure the quality of the final product.
-
One picture to read and adhere to follow-up - double standard parallel, heal the anterior gland
Time of Update: 2023-02-03
Execution: RudolfThis platform is designed to deliver more medical information to healthcare professionals.
Execution: RudolfThis platform is designed to deliver more medical information to healthcare professionals.
Execution: RudolfRudolfThis platform is designed to deliver more medical information to healthcare professionals.
-
CUA 2022|Professor Yao Yousheng: Current status of diagnosis and treatment of male urinary incontinence
Time of Update: 2023-02-03
prefaceOn December 9-11, 2022, the 29th National Urology Conference (CUA 2022), hosted by the Chinese Medical Association and the Urology Branch of the Chinese Medical Association, was held online. Ad
-
Research Frontiers The mental health problems of urolithiasis patients cannot be ignored
Time of Update: 2023-02-03
Fig. 2 Meta-analysis of urolithiasis and anxietyconclusionStudies have shown that there is a moderate and significant positive correlation between anxiety and urolithiasis, and that more people with urolithiasis experience psychological distress than expected, and researchers recommend that urological treatment teams treat urolithiasis patients in time to prevent unnecessary psychological distress.
-
Research Frontiers Can male grip strength reflect sperm quality?
Time of Update: 2023-02-03
Table 1 General demographic characteristics and sperm quality of participants stratified by quartile of grip strengthAfter adjusting for confounding factors, both the mixed-effects model (Table 2) and the restriction cubic spline model (Figure 1) showed that grip strength was positively correlated with semen volume, sperm density, forward motility sperm rate, total sperm motility, and total count (P 。 Compared with men in the lower quartile of grip strength, men in the upper quartile had 14.
-
CUA 2022 Professor Liu Zhuowei: Treatment strategies for high-risk NMIBC
Time of Update: 2023-02-03
Subsequently, Professor Liu Zhuowei's team conducted a prospective study to compare the efficacy of T1 high-grade bladder cancer, arterial chemotherapy and BCG bladder instillation, with the primary endpoint of 2-year recurrence-free survival (RFS) and secondary endpoints of PFS, CSS, and bladder preservation rate.
-
CUA 2022|Professor Qiao Ludong: 2022 "Guidelines for the Diagnosis and Treatment of Urinary Tract Infections" update points
Time of Update: 2023-02-03
The 2022 edition of CUA "Guidelines for the Diagnosis and Treatment of Urinary Tract Infections" has been officially published, on the occasion of this annual academic event, Professor Qiao Ludong of Beijing Tongren Hospital affiliated to Capital Medical University introduced the new developments and guidelines update highlights of urinary tract infections at home and abroad.
-
CUA 2022| Professor Liu Zhuowei: Treatment strategies for high-risk NMIBC
Time of Update: 2023-02-03
Subsequently, Professor Liu Zhuowei's team conducted a prospective study to compare the efficacy of T1 high-grade bladder cancer, arterial chemotherapy and BCG bladder instillation, with the primary endpoint of 2-year recurrence-free survival (RFS) and secondary endpoints of PFS, CSS, and bladder preservation rate.
-
Focus on the "chicken and egg problem" - the relationship between kidney stones and recurrent urinary tract infections
Time of Update: 2023-02-03
Table 1 KSD intervention modalities and UTI resultsThe results of a prospective cohort study in the UK showed that stone clearance (SFR) and infection clearance (IFR) at 3, 6, and 12 months postoperative in patients treated with URS were 96% vs 88%, 90% vs 86%, and 82% vs 71% (P), respectively, indicating a strong association between SFR and IFR.
-
TITAN Asian population data was released, and the deep decline of apatamide PSA was better than the global population
Time of Update: 2023-02-03
1]Apatamide regimens help Asian patients achieve this"Better PSA Deep Descent"The TITAN study[2] is undoubtedly a "milestone" in prostate cancer drug treatment.
1]Apatamide regimens help Asian patients achieve this"Better PSA Deep Descent"The TITAN study[2] is undoubtedly a "milestone" in prostate cancer drug treatment.
-
Clinical necessity Interstitial cystitis Chinese and Western medicine treatment
Time of Update: 2023-02-02
GuideInterstitial cystitis (IC) is a chronic inflammatory disease of the bladder characterized by chronic pelvic pain, urgency, frequency, routine urine examination and negative bacterial culture, which has a significant impact on the patient's quality of life and psychopsy.
-
"Evidence-based medicine" is convenient and practical! Do you know this prognostic indicator of renal cell carcinoma?
Time of Update: 2023-01-07
Research background The Prognostic Nutrition Index (PNI), a novel method to assess a patient's immune and nutritional status based on serum lymphocyte count and albumin levels, has been used in several studies to predict the prognosis of patients with renal cell carcinoma (RCC).
-
Professor Sun Ting From the beginning to the end, the optimization strategy of the whole process management of prostate cancer
Time of Update: 2023-01-07
With the implementation of the 2035 National Health Plan, Professor Sun Ting believes that more advanced treatment concepts and drugs will be introduced into the clinic in the future, and the diagnosis and treatment level of prostate cancer in China will be further improved, until it achieves synchronous development with the international frontier, and prostate cancer patients will also receive higher treatment guarantee and survival benefits.
-
Clinical necessity: Consensus on the safety of clinical application of urothelial carcinoma antibody conjugate drugs
Time of Update: 2023-01-07
The expert consensus recommends that the basic organ function of patients before ADC drug treatment should be fully evaluated, and patients with specific underlying diseases should be applied under close monitoring after excluding contraindications to ensure the safety of patients.
-
Research Frontier ARAMIS trial results update: treatment of nmCRPC patients, darolutamide can be expected in the future!
Time of Update: 2023-01-07
GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.